ReviewFuture medicinal chemistry2025
Ribonucleotide reductase (RNR) inhibitors as target-based weapon for future cancer drug development.
Review in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Venom-Derived Enzyme Inhibitors as Anticancer Agents: Structure-Activity Relationships, Molecular Targets and Mechanistic Insights.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains one of the leading causes of mortality worldwide, necessitating the development of precise and effective therapeutic strategies. Targeted cancer therapies aim to enhance treatment specificity while minimizing adverse effects. Ribonucleotide reductase (RNR), a key enzyme in Deoxyribonucleic acid (DNA) synthesis and cell division, has emerged as a critical target in cancer research. By inhibiting RNR, the production of deoxyribonucleotides is disrupted, ultimately impeding DNA replication and halting cancer cell proliferation. Given its essential role in cell cycle regulation, RNR inhibition represents a promising approach for anticancer therapy. This review highlights recent advances in the synthesis and biological evaluation of RNR inhibitors, emphasizing their potential as precision-targeted therapeutics. Furthermore, computational insights into their mechanism of action provide a foundation for designing next-generation inhibitors with enhanced potency and selectivity, paving the way for future pharmaceutical developments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.